After FDA Rejection, Humanigen's COVID-19 Drug Hopeful Sees Some Light Of Good News

Humanigen Inc HGEN announced that The Lancet Respiratory Medicine published results from its LIVE-AIR Phase 3 trial of lenzilumab in hospitalized COVID-19 patients.

  • The Lancet paper concludes, "LIVE-AIR showed that lenzilumab treatment of hospitalized patients with COVID-19 can improve the likelihood of survival without the need for mechanical ventilation, with a safety profile similar to that of placebo." 
  • Results of the LIVE-AIR Phase 3 trial demonstrate lenzilumab results in a statistically significant 54% relative improvement in the likelihood of survival without the need for invasive mechanical ventilation.
  • Lenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, said Cameron Durrant, Chairman & CEO, Humanigen.
  • According to the paper, '60% of LIVE-AIR patients were on room air or low-flow oxygen support...(Raising) the possibility of lenzilumab might be positioned for use before ICU admission and progression of respiratory failure requiring high-flow oxygen and non-invasive or invasive ventilation.'
  • Lenzilumab is a proprietary Humaneered first-in-class monoclonal antibody that has been proven to neutralize GM-CSF, a cytokine of critical importance in cytokine release syndrome associated with COVID-19 and other indications. 
  • In September, FDA declined Humanigen's request for emergency use authorization of its lenzilumab for newly hospitalized COVID-19 patients.
  • Price Action: HGEN shares are up 9.16% at $6.08 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!